- Home
- A-Z Publications
- Cardiovascular & Haematological Disorders - Drug Targets
- Previous Issues
- Volume 19, Issue 1, 2019
Cardiovascular & Haematological Disorders - Drug Targets - Volume 19, Issue 1, 2019
Volume 19, Issue 1, 2019
-
-
Role of AMPK in Diabetic Cardiovascular Complications: An Overview
Authors: Karthika Nellaiappan, Veera G. Yerra and Ashutosh KumarMacrovascular complications of diabetes like cardiovascular diseases appear to be one of the leading causes of mortality. Current therapies aimed at counteracting the adverse effects of diabetes on cardiovascular system are found to be inadequate. Hence, there is a growing need in search of novel targets. Adenosine Monophosphate Activated Protein Kinase (AMPK) is one such promising target, as a plethora of evidences point Read More
-
-
-
Humoral Immunity in Heart Failure
Authors: Amrita Sarkar and Khadija RafiqCardiovascular Disease (CVD) is a class of diseases that involve disorders of heart and blood vessels, including hypertension, coronary heart disease, cerebrovascular disease, peripheral vascular disease, which finally lead to Heart Failure (HF). There are several treatments available all over the world, but still, CVD and heart failure became the number one problem causing death every year worldwide. Both experimenta Read More
-
-
-
Recent Advances in Understanding the Pathogenesis of Cardiovascular Diseases and Development of Treatment Modalities
Cardiovascular Diseases (CVDs) are a leading cause of morbidity and mortality worldwide. The underlying pathology for cardiovascular disease is largely atherosclerotic in nature and the steps include fatty streak formation, plaque progression and plaque rupture. While there is optimal drug therapy available for patients with CVD, there are also underlying drug delivery obstacles that must be addressed. Challenges in drug de Read More
-
-
-
Nanoparticle Based Treatment for Cardiovascular Diseases
Authors: Purnima Gupta, Evelyn Garcia, Amrita Sarkar, Sumit Kapoor, Khadija Rafiq, Hitendra S. Chand and Rahul D. JayantNanotechnology has gained increased attention for delivering therapeutic agents effectively to the cardiovascular system. Heart targeted nanocarrier based drug delivery is a new, effective and efficacious approach for treating various cardiac related disorders such as atherosclerosis, hypertension, and myocardial infarction. Nanocarrier based drug delivery system circumvents the problems associated with convention Read More
-
-
-
Pseudomonas aeruginosa Invades Human Aortic Endothelial Cells and Induces Cell Damage in vitro
Authors: Rahul Mittal, Vasanti M. Jhaveri, Sae-In S. Kay, Patricia Blackwelder and Kunal PatelBackground: Cardiovascular diseases such as endocarditis are the second most common cause of death worldwide. Infective Endocarditis (IE) is the most severe infection of the heart associated with significant mortality and morbidity. The binding and invasion of Human Aortic Endothelial Cells (HAECs) by pathogenic microbes can play an important role in the pathogenesis of IE. Objective: Pseudomonas aeruginosa is an emergi Read More
-
-
-
Treatment of Lymphoid and Myeloid Malignancies by Immunomodulatory Drugs
By Ota FuchsThalidomide and its derivatives (lenalidomide, pomalidomide, avadomide, iberdomide hydrochoride, CC-885 and CC-90009) form the family of immunomodulatory drugs (IMiDs). Lenalidomide (CC5013, Revlimid®) was approved by the US FDA and the EMA for the treatment of multiple myeloma (MM) patients, low or intermediate-1 risk transfusion-dependent myelodysplastic syndrome (MDS) with chromosome 5q deleti Read More
-
-
-
In Situ Oxidative Stress and Atrial Cell Deaths in Patients with Valve Disease
Authors: Bashir M. Matata and Maqsood M. ElahiBackground: Left ventricular hypertrophy and myocardial remodeling occur with aortic valve disease and may lead to heart failure. Although increased oxidative stress and inflammatory factors have been implicated in heart failure, their role in the progression of valve disease remains unclear. Objectives: We investigated the role of oxidative stress and inflammatory factors in valve disease whether this relates to cell de Read More
-
Volumes & issues
-
Volume 24 (2024)
-
Volume 23 (2023)
-
Volume 22 (2022)
-
Volume 21 (2021)
-
Volume 20 (2020)
-
Volume 19 (2019)
-
Volume 18 (2018)
-
Volume 17 (2017)
-
Volume 16 (2016)
-
Volume 15 (2015)
-
Volume 14 (2014)
-
Volume 13 (2013)
-
Volume 12 (2012)
-
Volume 11 (2011)
-
Volume 10 (2010)
-
Volume 9 (2009)
-
Volume 8 (2008)
-
Volume 7 (2007)
-
Volume 6 (2006)
Most Read This Month
Article
content/journals/chddt
Journal
10
5
false
en
